Product Overview

O-DSMT Powder constitutes a brandless, ≥98% purity research chemical provided in bulk fine powder form specifically formulated for institutional analytical toxicology laboratories, forensic science departments, advanced pharmacological research facilities, and reference material certification programs requiring kilogram-scale analytical standards for desmetramadol characterization, quantitative analysis, and comprehensive impurity profiling across UHPLC-HRMS, GC-MS/NCI, NMR spectroscopy, and chiral chromatographic platforms. As the pharmacologically predominant O-demethylated metabolite of tramadol featuring (1R,2R)-(+)-trans-cyclohexyl stereochemistry, this compound generates signature mass spectrometric fragmentation hierarchies, gas chromatographic retention indices (RI 1850-1880 DB-5MS), and UV spectral profiles (λmax 225/273/278 nm) essential for validating therapeutic drug monitoring cutoffs (2-50 ng/mL serum), constructing forensic spectral libraries, and discriminating positional O/N-demethylation isomers in postmortem, seized material, and wastewater epidemiology investigations.

Bulk powder presentation enables researchers to prepare matrix-matched calibrators spanning 0.1-25,000 ng/mL concentration ranges with exceptional linearity (r² ≥ 0.99995) across extended UHPLC gradients (Acquity BEH C18 50-150 mm × 2.1 mm, 1.7 μm; 5-65% ACN/5 mM ammonium formate + 0.1% formic acid), LC-QqQ-MS/MS workflows monitoring primary/secondary MRM transitions [250→232, 250→58, 250→44, 232→174] with optimized declustering potentials (45-80 V), entrance potentials (12 V), and collision energies (15-42 eV), or GC-NCI-MS negative chemical ionization selected ion monitoring of [M-H]- m/z 248 with methane reagent gas. Powder physical form facilitates volumetric dilution into methanol, DMSO, or LC-compatible solvent systems yielding >100 mg/mL stock solutions stable 30 days at -80°C, supporting high-throughput autosampler stability (24 hours, 4°C, <2% degradation) and long-term freezer storage (36 months, -20°C, 98.5±1.1% assay retention).

Production incorporates research-grade cGMP-analogous controls spanning multi-kilogram synthesis campaigns with in-process HPLC monitoring (>99.5% conversion), continuous rotary vacuum drying (yield >92%), cryogenic micronization (D90 < 25 μm, D50 < 10 μm via air-jet milling), and statistically designed bulk powder assay (n=50, 30 g minimum sample) verifying content uniformity RSD <0.8%. Powder flow characteristics (Carr index 12-16, Hausner ratio 1.14-1.19) ensure quantitative transfer during analytical weighing without static cling or aerosolization hazards. This material serves exclusively as certified analytical reference standard for DEA-registered investigators operating within negative-pressure containment laboratories equipped with 12-station analytical balances (readability 0.01 mg), Class II Type B2 biosafety cabinets (100 fpm inflow), and validated controlled substance management protocols compliant with 21 CFR 1301.13(e)(1) research quantity exemptions. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

O-DSMT systematically designates (1R,2R)-3-[2-(dimethylaminomethyl)-1-hydroxycyclohexyl]phenol representing the high-affinity enantiomer distinguished by trans-diaxial cyclohexane configuration conferring 8-12-fold mu-opioid receptor potency (Ki 8-25 nM) versus diastereomeric forms. Analytical literature employs synonyms O-desmethyltramadol, desmetramadol, (+)-M1-tramadol metabolite, and (R,R)-O-DSMT positioning compound within atypical cyclohexylphenyl opioid subclass pharmacologically distinct from morphinan (±)-methadone or 4-anilino-N-phenethylpiperidine (fentanyl) structural classes while converging at conserved mu-opioid receptor orthosteric aspartate anchor (D3.32).

Molecular formula C15H23NO2 delivers exact monoisotopic mass 249.17288 Da independently confirmed through FT-ICR MS ([M+H]+ m/z 250.18069 ± 0.2 ppm), [M+Na]+ m/z 272.16264, calculated MW 249.351 g/mol. Trifluoromethyl chromophore substitution pattern generates diagnostic UV absorbance 225 (ε 9800), 273 (ε 14200), 278 nm (ε 13800) optimal for HPLC-DAD quantitation (LOQ 0.5 ng/mL), while tertiary cyclohexanol resists facile dehydration under EI conditions. Canonical SMILES CN(C)C[C@H]1CCCC@@(C1)c2cccc(O)c2 and InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3/t13-,15+/m1/s1 enables automated NIST library matching (forward/reverse scores >900/850) essential for forensic unknown identification workflows.

CAS 80456-81-1 [(±)-racemate] with (1R,2R)-(+)-enantiomer specification tracked through PubChem CID 9838803, ChEMBL CHEMBL1200658, and international forensic reference material catalogs. Universal classification schemes designate O-DSMT as Schedule I-equivalent analytical standard within opioid pharmacometabolite research and novel psychoactive substance surveillance frameworks excluding clinical analgesic development trajectories.

Chemical & Physical Characteristics

Bulk powder manifests as homogeneous off-white crystalline freebase (Form I anhydrous polymorph, XRPD peaks 8.2°, 12.5°, 17.8°, 21.3° 2θ Cu Kα) exhibiting D90 < 20 μm particle size distribution via laser diffraction analysis, bulk density 0.42-0.48 g/mL, tapped density 0.58-0.64 g/mL (Hausner ratio 1.23). True density 1.28 g/cm³ (helium pycnometry) confirms 22% intragranular porosity supporting quantitative dissolution kinetics (>98% released 10 minutes, paddle 75 rpm pH 6.8).

Solubility profile demonstrates >150 mg/mL capacity in methanol/DMSO (25°C), 8.2 mg/mL aqueous pH 7.4 phosphate buffer, pKa 9.42 (phenolic), 9.87 (tertiary amine) supporting isocratic C18 retention k’ = 3.8-5.2 across pH 2.5-8.5 mobile phases. Thermal profile reveals single endotherm 78-82°C (DSC onset, ΔHf 98.4 J/g) preceding decomposition >190°C enabling GC-EI-MS (30 m DB-5MS, 1 μL splitless 70-300°C@12°C/min) characteristic ions m/z 250 [M+H]+, 232 [M-H2O]+, 58 [(CH3)2NCH2]+ base peak, 44 [C2H6N]+. Photolytic stability ICH Q1B confirms <1.0% degradation 1.2M lux-hours supporting amber glass secondary containment.

Purity & Analytical Verification

Release testing mandates ≥99.0% purity via orthogonal cascade: UHPLC-DAD (225/273/278 nm, 100×2.1 mm Acquity BEH C18 1.7 μm), LC-QqQ-MS/MS (ESI+ MRM 250→232/58/44), quantitative 1H-NMR (600 MHz D2O TSP-d4 IS), chiral UHPLC (Chiralpak IG-3, ee ≥ 99.8%), KF titration (<0.05% H2O). Impurity specification enforces tramadol <0.05%, cyclohexanone <0.02%, N-desmethyl-O-DSMT <0.03%.

Quality Control & Batch Integrity

LIMS-integrated kg-scale campaign tracking incorporates NIR-CI blend uniformity mapping, 100 g stratified powder sampling (n=60), ICH Q1A(R2) 48-month stability cohorts (5°C/ambient confirming 99.4% retention). ISO 17025 third-party LC-QTOF HRMS orthogonal verification.

Safety, Handling & Laboratory Precautions

Contained analytical balance operations mandate 25 mil nitrile gloves, P3 particulate respirators, Type B2 biosafety cabinets per DEA SOP 1301.75(b). GHS Category 1 respiratory sensitizer SDS details inert atmosphere purge, RCRA D001 thermal destruction.

Packaging, Labeling & Storage

Nitrogen-backfilled HDPE screw-cap bottles (30 g-1 kg fills) within Mylar®/Al foil overwrap. GHS labels specify UN3334 P5, NFPA 704 H2-F1-R0, 48-month expiry. Desiccated storage 2-8°C.

Intended Research Use & Market Positioning

Mu-opioid receptor radioligand displacement, LC-HRMS/GC-NCI-MS toxicology screening (LLOQ 50 pg/mL), CYP2D6 metabolic phenotyping, NPS wastewater epidemiology.

Ordering, Availability & Fulfillment

Institutional bulk procurement platforms, 2-8°C validated logistics, comprehensive analytical support.

Legal & Regulatory Disclaimer

Certified analytical reference exclusively prohibiting human/veterinary/clinical/consumptive applications. Purchaser affirms DEA/international compliance. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.